Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
Derma Sciences Capex-to-Operating-Income Historical Data
The historical data trend for Derma Sciences's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Derma Sciences's Capex-to-Operating-Income
For the Medical Instruments & Supplies subindustry, Derma Sciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Derma Sciences's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Derma Sciences's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Derma Sciences's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Derma Sciences Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of Derma Sciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Derma Sciences (Derma Sciences) Business Description
Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. In addition, the Company owns or licenses over 50 U.S. patents, corresponding foreign patents and patent applications. The patents relating to the DSC127, MEDIHONEY, BIOGUARD, AMNIOEXCEL and AMNIOMATRIX technologies are held under license agreements of indefinite duration. It is subject to the regulation regarding occupational safety, laboratory practices, environmental protection and hazardous substance control and may be subject to other present and future U.S. and foreign regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DSCI has been successfully added to your 